2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

HL-60 acute myeloid leukemia cells

" in MedChemExpress (MCE) Product Catalog:

20

Inhibitors & Agonists

3

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-12892
    SKI-178
    1 Publications Verification

    		 SphK Apoptosis Cancer
    SKI-178 is a potent sphingosine kinase-1 (SphK1) and SphK2 inhibitor. SKI-178 is cytotoxic at IC50 concentrations ranging from 1.8 to 0.1 μM in both agent sensitive and multi-agent resistant cancer cell lines (i.e., MTR3, NCI-ADR and HL60/VCR cells). SKI-178 induces apoptosis in a CDK1-dependent manner in human acute myeloid leukemia cell lines .
    SKI-178
  • HY-113455
    9(S)-HODE

    Alpha-dimorphecolic acid

    		 Endogenous Metabolite Apoptosis Drug Derivative Cancer
    9(S)-HODE (Alpha-dimorphecolic acid) is the major active derivative of Linoleic acid (HY-N0729). 9(S)-HODE regulates the expression of miR-361-3p. 9(S)-HODE reduces cancer cell viability and induces cancer cell apoptosis. 9(S)-HODE can be used in the research of acute myeloid leukemia .
    9(S)-HODE
  • HY-133136
    PROTAC BRD4 Degrader-2

    		PROTACs Epigenetic Reader Domain Cancer
    PROTAC BRD4 Degrader-2 is a PROTAC connected by ligands for Cereblon and BRD4 with an IC50 of 14.2 nM against BRD4 BD1 .
    PROTAC BRD4 Degrader-2
  • HY-138632
    PROTAC BRD4 Degrader linker conjugate

    		PROTACs Epigenetic Reader Domain PROTAC-Linker Conjugates for PAC Cancer
    PROTAC BRD4 Degrader linker conjugate is a linker-payload conjugate as well as a bifunctional degrader of BRD4 that binds to VHL, consisting of PROTAC and a linker. PROTAC BRD4 Degrader linker conjugate can be conjugated with STEAP1 and CLL1 antibodies to degrade BRD4 protein, with DC50 values of 0.86 nM and 7.6 nM, respectively. PROTAC BRD4 Degrader linker conjugate can be used in research related to prostate cancer and acute myeloid leukemia (BRD4 ligand: (HY-129939); VHL ligand: (HY-125845)) .\n
    PROTAC BRD4 Degrader linker conjugate
  • HY-155066
    FD274

    		PI3K mTOR Apoptosis Cancer
    FD274 is a highly potent PI3K/mTOR dual inhibitor with IC50s of 0.65 nM, 1.57 nM, 0.65 nM, 0.42 nM, and 2.03 nM against PI3Kα/β/γ/δ and mTOR, respectively. FD274 exhibits significant anti-proliferation of AML cell lines (HL-60 and MOLM-16). FD274 arrests HL-60 cell cycle at G1 phase and increases apoptosis. FD274 demonstrates dose-dependent inhibition of tumor growth in the HL-60 xenograft model. FD274 has the potential for acute myeloid leukemia research .
    FD274
  • HY-142696A
    CDK6/PIM1-IN-1 hydrochloride

    		CDK Pim Apoptosis Cancer
    CDK6/PIM1-IN-1 (Compound 51) hydrochloride is an orally active and potent dual CDK6/PIM1 inhibitor with IC50 values of 39 and 88 nM, respectively. CDK6/PIM1-IN-1 hydrochloride inhibits CDK4 (IC50=3.6 nM). CDK6/PIM1-IN-1 hydrochloride significantly inhibits acute myeloid leukemia (AML) cell proliferation, arrest cell cycle at the G1 phase, and promote cell apoptosis. CDK6/PIM1-IN-1 exhibits potent anti-AML activity .
    CDK6/PIM1-IN-1 hydrochloride
  • HY-142696
    CDK6/PIM1-IN-1

    		CDK Pim Apoptosis Cancer
    CDK6/PIM1-IN-1 is a potent and balanced dual CDK6/PIM1 inhibitor with IC50 values of 39 and 88 nM, respectively. CDK6/PIM1-IN-1 inhibits CDK4 (IC50=3.6 nM). CDK6/PIM1-IN-1 significantly inhibits acute myeloid leukemia (AML) cell proliferation, arrest cell cycle at the G1 phase, and promote cell apoptosis. CDK6/PIM1-IN-1 exhibits potent anti-AML activity .
    CDK6/PIM1-IN-1
  • HY-18051
    CXL 017

    		Calcium Channel Cancer
    CXL 017 is a sarco/endoplasmic reticulum Ca 2+-ATPase (SERCA) inhibitor. CXL 017 can inhibit the ATPase activity of SERCA by competing with ATP for binding. CXL 017 exhibits selective cytotoxicity against multidrug-resistant acute myeloid leukemia cells HL60/MX2. CXL 017 can be used in the research of tumors such as multidrug-resistant acute myeloid leukemia .
    CXL 017
  • HY-N12641
    Ardisianone

    		Apoptosis Pyroptosis Cancer
    Ardisianone is a component with an alkyl benzoquinone structure that can be isolated from Ardisia virens Kurz and Ardisia compressa tea extract. Ardisianone exhibits potent antileukemic activity, particularly against HL-60 cells, with IC50 values of 1.87 μM (24 h) and 1.67 μM (48 h). Ardisianone induces caspase-dependent apoptosis and triggers pyroptosis. Ardisianone can be used for the study of acute myeloid leukemia (AML) .
    Ardisianone
  • HY-161708
    PROTAC FLT3/CDKs degrader-1

    		PROTACs CDK FLT3 Cancer
    PROTAC FLT3/CDKs degrader-1 (Compound C3) is a degrader for cyclin-dependent kinases (DC50 is 18.73 nM for CDK2) and the FMS-like tyrosine kinase 3 (FLT3). PROTAC FLT3/CDKs degrader-1 induces differentation of HL-60 (72.77% differentation at 6.25 nM), inhibits proliferation of AML cells, with IC50s of 2.9-37 nM. PROTAC FLT3/CDKs degrader-1 is potential for ameliorating acute myeloid leukemia. (Pink: ligand for target protein FLT3/CDKs ligand-1 (HY-161709); Black: linker (HY-W012935); Black: ligand for E3 ligase Thalidomide 5-fluoride (HY-W087383))
    PROTAC FLT3/CDKs degrader-1
  • HY-172153
    CDK2-IN-41

    		CDK Reactive Oxygen Species (ROS) Apoptosis Cancer
    CDK2-IN-41 (Compound 7a) is a CDK2 inhibitor that exerts anticancer activity by binding to CDK2, thereby inhibiting the cell cycle, inducing cytotoxicity, promoting ROS production, and triggering Apoptosis. CDK2-IN-41 exhibits an IC50 of 10 µM against acute myeloid leukemia (AML) HL-60 cells. It holds potential for research in AML-related cancer therapy .
    CDK2-IN-41
  • HY-173123
    LSD1-IN-40

    		Histone Demethylase Apoptosis Cancer
    LSD1-IN-40 (Compound 9e) is a potent LSD1 inhibitor, with an IC50 of 9.85 nM. LSD1-IN-40 exhibits exceptional selectivity for LSD1 over both MAOs and hERG. LSD1-IN-40 exhibits significant inhibitory activity against leukemia cells (MV-4-11, HL-60, and THP-1 cells). LSD1-IN-40 can induce apoptosis in MV-4-11 cells. LSD1-IN-40 has the potential for the research of acute myeloid leukemia .
    LSD1-IN-40
  • HY-131496
    ortho-Topolin riboside

    		STAT Cancer
    ortho-Topolin riboside is a naturally occurring cytokinin secreted from Populus x robusta leaves after sunrise. ortho-Topolin riboside has shown unique cytotoxic activity against NCI60 cell lines compared with the activity of other cytokinins.ortho-Topolin riboside induced differentiation through inhibition of STAT3 signaling in acute myeloid leukemia HL-60 cells.
    ortho-Topolin riboside
  • HY-177714
    14-Acetoxy parthenolide

    		Drug Derivative Cancer
    14-Acetoxy parthenolide (compound 6a) is a parthenolide (PTL) derivative. 14-Acetoxy parthenolide exhibits potent anti-acute myeloid leukemia (AML) activity against HL-60 and KG1a cells, with IC50 values of 2.8 µM and 6.3 µM, respectively. 14-Acetoxy parthenolide can be used for AML research .
    14-Acetoxy parthenolide
  • HY-181023
    PROTAC HDAC8 Degrader-3

    		PROTACs HDAC Cancer
    PROTAC HDAC8 Degrader-3 (Compound BP1) is an efficient and selective HDAC8 PROTAC degrader with a DC50 of 20 nM. PROTAC HDAC8 Degrader-3 exhibits IC50 for HDAC8 and CRBN of 0.46 and 7.5 μM, respectively. PROTAC HDAC8 Degrader-3 exhibits potent anti-proliferative activity against MM.1S and HL-60 cells. PROTAC HDAC8 Degrader-3 can be used for research on multiple myeloma and acute myeloid leukemia .
    PROTAC HDAC8 Degrader-3
  • HY-N8177
    Bletilloside A

    		NO Synthase Inflammation/Immunology Cancer
    Bletilloside A is a glycoside. Bletilloside A can be isolated from the tubers of Bletilla striata. Bletilloside A inhibits the expression of the TCL1A protein. When evaluated for its inhibitory activity against LPS-induced NO, Bletilloside A shows an IC50 of >70 μM. Bletilloside A exhibits anticancer activity against acute myeloid leukemia. Bletilloside A can be used in studies related to acute myeloid leukemia .
    Bletilloside A
  • HY-183683
    DQ-9

    		Proteasome Apoptosis Cancer
    DQ-9 is a selective immunoproteasome β5i inhibitor (IC50=0.0019 μM). DQ-9 generates additional inhibitory substances via iron-mediated intracellular activation, and induces oxidative stress, carbon-centered free radicals and macromolecular damage through its artemisinin domain. DQ-9 induces apoptosis in leukemia and multiple myeloma cells. DQ-9 exhibits selective cytotoxicity against leukemia and multiple myeloma cells by elevating the labile iron pool. DQ-9 can be used in the research of hematological malignancies (leukemia, multiple myeloma, mantle cell lymphoma, acute myeloid leukemia) .
    DQ-9
  • HY-181678
    DNA-PK/HDAC6-IN-1

    		DNA-PK HDAC Apoptosis Mitochondrial Metabolism DNA/RNA Synthesis Cancer
    DNA-PK/HDAC6-IN-1 is a selcetive and orally active dual DNA-PK and HDAC6 inhibitor with IC50 values of 84.2 and 64.8 nM. DNA-PK/HDAC6-IN-1 suppresses cancer cells proliferation, induces cancer cell cycle G2/M arrest, apoptosis, and decreases the mitochondrial membrane potential. DNA-PK/HDAC6-IN-1 induces DNA damage and elevates γ-H2AX levels. DNA-PK/HDAC6-IN-1 exhibits antitumor efficacy in AML animal mouse model. DNA-PK/HDAC6-IN-1 can be used for the research of acute myeloid leukemia .
    DNA-PK/HDAC6-IN-1
  • HY-148014
    TH7299

    		Methylenetetrahydrofolate Dehydrogenase (MTHFD) Parasite Apoptosis DNA/RNA Synthesis Infection Cancer
    TH7299 is a TbFolD inhibitor with antiparasitic activity. TH7299 binds the tetrahydrofolate-binding pocket of MTHFD2, and inhibits MTHFD2L and the dehydrogenase/cyclohydrolase domain of MTHFD1. TH7299 reduces cancer cells viability, induces apoptosis, DNA damage. TH7299 can be used for the researches of african trypanosomiasis and acute myeloid leukemia.
    TH7299
  • HY-182550
    Indoluidin D

    		Dihydroorotate Dehydrogenase Cancer
    Indoluidin D is a selective dihydroorotate dehydrogenase (DHODH) inhibitor with a human DHODH IC50 of 210 nM. Indoluidin D selectively inhibits human DHODH activity, with induced effects rescuable by orotic acid. Indoluidin D promotes myeloid differentiation and inhibits cancer cell proliferation. Indoluidin D can be used for the research of acute promyelocytic leukemia .
    Indoluidin D

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: